PROS-VARIANT
Financiado
PIK3CA-Related Overgrowth Spectrum: molecular mechanisms and preclinical modelling of PIK3CA VARIANTs
PIK3CA-related overgrowth spectrum (PROS) is a group of rare congenital disorders that manifest as complex syndromes with overgrowth of several tissues (vasculature, adipose and muscle tissues, bones, brain and skin among others)...
PIK3CA-related overgrowth spectrum (PROS) is a group of rare congenital disorders that manifest as complex syndromes with overgrowth of several tissues (vasculature, adipose and muscle tissues, bones, brain and skin among others) or as localized lesions such as vascular malformations. PROS is caused by somatic activating mutations in the PIK3CA gene that arise postzigotically during embryonic development. Patients suffer dramatic functional and life-threatening complications and typically require extensive mutilating surgery, pulsed laser, and/or sclerotherapy. However, these treatment strategies are insufficient, and patients commonly experience a high risk of recurrence and progression. This is in part a reflection of poor understanding of the underlying cellular and molecular mechanism of their onset and progression. In this proposal, I aim to gain physiological and molecular insight into PROS and address fundamental biological questions concerning when (timing), where (cell linage), who (PIK3CA variant) and how (triggered mechanism) activating PIK3CA variants contribute to the development and severity of PROS. I will address the following key objectives: 1) identify the specific molecular and cellular alterations triggered by strong (H1047R) and weak (E726K) activating PIK3CA variants and 2) characterize their spatiotemporal pathogenesis in PROS using novel mice models. To this end, a combination of in vitro and in vivo approaches, using novel genetically modified mice will be implemented in order to provide new mechanistic insight into the underlying disease pathology and give rise to new preclinical models to test therapeutic treatments. Achieving these goals will strongly contribute to my training as international expert in PI3K signaling, cell biology and congenital diseases, my experimental skillset, and my development towards a well-embedded and independent researcher within European academia.
ver más
Duración del proyecto: 23 meses
Fecha Inicio: 2022-09-01
Fecha Fin: 2024-08-31
Fecha Fin: 2024-08-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2024-08-31
H2020
No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Presupuesto
El presupuesto total del proyecto asciende a
161K€
Líder del proyecto
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEM...
No se ha especificado una descripción o un objeto social para esta compañía.
